{
    "clinical_study": {
        "@rank": "82404", 
        "arm_group": {
            "arm_group_label": "Ocriplasmin", 
            "arm_group_type": "Experimental", 
            "description": "Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to observe the anatomical and functional outcomes of\n      ocriplasmin  (JETREA\u00ae) over a 6-month follow-up period."
        }, 
        "brief_title": "Assessment of Patients Treated With JETREA\u00ae for Vitreomacular Traction", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Vitreomacular Traction", 
            "Vitreomacular Adhesion"
        ], 
        "condition_browse": {
            "mesh_term": "Tissue Adhesions"
        }, 
        "detailed_description": {
            "textblock": "Subjects will be recruited from approximately 90 centers in approximately 11 countries\n      across Europe and Canada. After receiving a single intravitreal injection as per country's\n      product label (Day 0), subjects will be followed for a 6-month period (Day 180)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of vitreomacular traction/symptomatic vitreomacular adhesion (VMT/sVMA),\n             with evidence of focal VMT visible on Spectral Domain Optical Coherence Tomography\n             (SD-OCT).\n\n          -  Read, sign, and date an Institutional Review Board/Ethics Committee-approved informed\n             consent form.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Women of childbearing potential if pregnant, breastfeeding, or not in agreement to\n             use adequate birth control methods to prevent pregnancy throughout the study.\n\n          -  Hypersensitivity to ocriplasmin or any of the JETREA excipients.\n\n          -  Active or suspected intraocular or periocular infection.\n\n          -  Presence of Epiretinal Membrane (ERM) over the macula at baseline.\n\n          -  Broad VMT/VMA >1500 microns at baseline.\n\n          -  History of vitrectomy in the study eye.\n\n          -  History of laser photocoagulation to the macula in the study eye.\n\n          -  Any relevant concomitant ocular condition that, in the opinion of the investigator,\n             could be expected to worsen or require surgical intervention during the study period.\n\n          -  Macular hole of >400\u00b5m diameter in the study eye.\n\n          -  High myopia in the study eye.\n\n          -  Pseudo-exfoliation, Marfan's syndrome, phacodonesis or any other finding in the\n             Investigator's opinion suggesting lens/zonular instability.\n\n          -  Aphakia.\n\n          -  History of retinal detachment.\n\n          -  Diabetic retinopathy, ischaemic retinopathies, retinal vein occlusions.\n\n          -  Recent ocular surgery or ocular injection.\n\n          -  Vitreous hemorrhage.\n\n          -  Exudative age-related macular degeneration (AMD).\n\n          -  Therapy with another investigational agent within 30 days prior to Visit 1.\n\n          -  Active, simultaneous enrollment in another ophthalmology clinical study.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035748", 
            "org_study_id": "M-13-056", 
            "secondary_id": "2013-005464-25"
        }, 
        "intervention": {
            "arm_group_label": "Ocriplasmin", 
            "intervention_name": "Ocriplasmin 0.125 mg in a 0.1 mL volume", 
            "intervention_type": "Drug", 
            "other_name": "JETREA\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Vitreomacular traction", 
            "Symptomatic vitreomacular adhesion", 
            "Ocriplasmin", 
            "JETREA"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Assessment of Anatomical and Functional Outcomes in Patients Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Danyel C Carr, MS, CCRA", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "European Union: European Medicines Agency", 
                "Belgium: Ethics Committee", 
                "Canada: Ethics Review Committee", 
                "France: Committee for the Protection of Personnes", 
                "Germany: Ethics Commission", 
                "Hungary: Institutional Ethics Committee", 
                "Italy: Ethics Committee", 
                "Netherlands:  Independent Ethics Committee", 
                "Poland: Ethics Committee", 
                "Portugal: Ethics Committee", 
                "Spain: Ethics Committee", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of subjects with nonsurgical resolution of focal vitreomacular traction (VMT/VMA) at Day 28, as determined by Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD\u2010OCT) evaluation", 
            "safety_issue": "No", 
            "time_frame": "Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035748"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in best-corrected visual acuity (BCVA) at distance", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 0), up to Day 180"
            }, 
            {
                "measure": "Proportion of subjects with closure of macular hole (MH), if present at baseline", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 180"
            }, 
            {
                "measure": "Proportion of subjects with nonsurgical resolution of VMT/sVMA", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 180"
            }, 
            {
                "measure": "Proportion of subjects experiencing pars plana vitrectomy (PPV) at Day 180", 
                "safety_issue": "No", 
                "time_frame": "Day 180"
            }, 
            {
                "measure": "Change from baseline in central foveal thickness", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 180"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}